SCHEMBL3101167

SCHEMBL3101167

COc1cncc(-c2cc(C(Cl)C3CCCCC3)c(C)o2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 5/20 0.36
CHRNA4 P43681 3/20 0.36
CYP11B1 P15538 6/20 0.36
CYP11B2 P19099 6/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
PTGS2 P35354 1/20 0.34
CHRNB4 P30926 4/20 0.33
CHRNA3 P32297 4/20 0.33
FYN P06241 2/20 0.33
CHRNA7 P36544 2/20 0.33
CYP1A1 P04798 1/20 0.33
CYP1B1 Q16678 1/20 0.33
CHRNB1 P11230 2/20 0.32
CHRNB3 Q05901 2/20 0.32
CYP17A1 P05093 1/20 0.32
PDE1A P54750 1/20 0.32
PDE1B Q01064 1/20 0.32
PDE1C Q14123 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3101188 0.86 IDO1 (0.38) CHRNB2CHRNA4CYP11B1CYP11B2CYP1A2
SCHEMBL3093911 0.86 CYP2A6 (0.34) CYP1A2PTGS2CYP1A1CYP1B1
SCHEMBL3106764 0.79 PDE4A (0.41) CYP11B2CYP1A2CYP3A4CYP2C9CYP1A1
SCHEMBL3099728 0.79 MMP13 (0.41)
SCHEMBL3106759 0.78 PDE4A (0.37) CYP1A2CYP3A4CYP2C9PDE4A
SCHEMBL3107059 0.75 MAOB (0.37) CYP1A2CYP3A4CYP2C9
SCHEMBL3101526 0.75 CYP11B1 (0.38) CYP11B1CYP11B2CYP1A2CYP3A4CYP2C9
SCHEMBL3105333 0.75 AXL (0.37)
SCHEMBL3106612 0.75 HRH3 (0.33) PTGS2
SCHEMBL3111558 0.75 RCE1 (0.43) PTGS2MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR CHRNB2 2323/4885CHRNA4 1972/4885CYP11B1 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.